Medical devices, healthcare technology and the business of care
PMA approval · P250023

Allurion Gastric Balloon System

Allurion Technologies, Inc. · Decision date Feb 20, 2026

MEDTECHLEDGER EXPLANATIONP250023

What did the FDA approve?

The FDA database record P250023 shows an approval decision dated 2026-02-20 for the Allurion Gastric Balloon System (AGBS), submitted by Allurion Technologies, Inc. under product code LTI, device category "IMPLANT, INTRAGASTRIC FOR MORBID OBESITY." The record lists no supplement type or supplement reason, so the fields supplied do not identify a prior PMA or establish any change from an earlier cleared scope; the decision is described only as an approval.

Per the source statement, the approved indication covers short-term limited weight loss in adults aged 22 to 65 years with BMI from 30 to 40 kg/m2 who have had at least one unsuccessful weight loss program attempt. The system is to be used with a moderate intensity lifestyle modification therapy program, consists of up to two Allurion Balloons placed during a 10-month period, and has a variable residence time averaging 15.3 weeks. This is the applicant's stated purpose, not independent evidence of safety or clinical effectiveness.

FDA approval order statement

Approval for the Allurion Gastric Balloon System (AGBS) is indicated to promote short-term limited weight loss in adult individuals with obesity between the ages of 22 years and 65 years with a body mass index (BMI) greater than or equal to 30 kg/m2 and less than or equal to 40 kg/m2 who have had at least one unsuccessful attempt at a weight loss program. The residence time for each AGBS is variable with an average observed residence time of 15.3 weeks. The AGBS is to be used in conjunction with a moderate intensity lifestyle modification therapy program. The AGBS consists of up to two Allurion Balloons placed during a 10-month period.
Regulatory pathway
Original PMA
Clinical specialty
Gastroenterology, Urology
Decision date
Feb 20, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250023
Regulatory pathway
Premarket approval application
Product code
LTI
Decision code
APPR
Decision date
Feb 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: IMPLANT, INTRAGASTRIC FOR MORBID OBESITY.

Product code
LTI
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250023 received

    Application receipt date recorded by FDA.

  2. P250023 · FDA decision

    APPR

  3. P250023/S001 · Related supplement

    Allurion Gastric Balloon System

  4. P250023/S002 · Related supplement

    Allurion Gastric Balloon System

Timeline entries are records held by MedtechLedger for P250023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250023

Product / regulatory recordCompanyPathwayDecision dateSource
Allurion Technologies, Inc.PMA supplementSep 9, 2026FDA
Allurion Technologies, Inc.PMA supplementSep 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allurion Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
11 Huron Dr., Natick, MA, 01760

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records